Adicet Bio Q2 net loss narrows

ADICET Bio

05/08/2026 22:16

Overview
US cell therapy developer posted Q2 net loss of $21.4 mln, or $1.99 per share
Company expects Phase 1 prula-cel clinical update in lupus nephritis/SLE in Q3/2026
Interim chief medical officer appointed after leadership change

Outlook
Adicet expects topline Phase 1 prula-cel data in LN and SLE in 3Q/2026
Company plans to start pivotal prula-cel trial in LN in 2H/2026, pending regulatory clearance
Regulatory filing for ADI-212 in mCRPC expected in 3Q/2026; Phase 1 enrollment to begin 4Q/2026

Result Drivers
R&D SPENDING - Higher research and development expenses driven by advancement of prula-cel and ADI-212 programs
PIPELINE PROGRESS - Company cited progress in clinical and regulatory milestones for prula-cel and ADI-212
LEADERSHIP CHANGE - Appointment of interim chief medical officer following executive departure

Company press release: ID:nBw44JzV0a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$1.99
 
Q2 Net Loss
 
$21.36 mln
 
Q2 Operating Expenses
 
$22.3 mln
 
Q2 Operating Income
 
-$22.3 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for ADICET Bio, Inc. is $22.50, about 144.3% above its August 4 closing price of $9.21

Reuters Recommended Reads
Aug 4 - Dianthus Therapeutics Q2 net loss widens as R&D costs rise
Aug 4 - Tyra Biosciences Q2 net loss widens on higher R&D expenses
Aug 4 - Spyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)